

Special Issue

Hope Amidst Challenges: Therapies for Relapsed/Refractory Multiple Myeloma

Message from the Guest Editor

Despite recent progress, multiple myeloma remains incurable for most patients. While treatment options have expanded and advances in frontline therapy have improved outcomes, they have also introduced new challenges in managing relapsed/refractory disease (RRMM). A major obstacle is the limited global availability of novel therapies, with regulatory delays and high costs contributing to significant disparities in access. Nevertheless, improvements in progression-free survival and overall survival have been achieved over the past decade, driven by the rapid growth in therapeutic classes and combination strategies with the introduction of quadruplet therapy in the frontline, CAR T-cells, bispecific antibodies, and antibody drug conjugates (ADCs) in the relapse setting. Another key challenge is the interpretation and clinical application of minimal residual disease (MRD). Critical questions remain regarding optimal timing for treatment discontinuation in MRD-negative patients and reinitiation upon MRD conversion, highlighting the need for further evidence to guide MRD-driven therapeutic decisions.

Guest Editor

Dr. Martha L. Louzada

London Health Sciences Centre, Victoria Hospital, London, ON N6A 5W9, Canada

Deadline for manuscript submissions

20 March 2027



Current Oncology

an Open Access Journal
by MDPI

Impact Factor 3.6
CiteScore 6.1
Indexed in PubMed



mdpi.com/si/257842

Current Oncology
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
currentoncology@mdpi.com

[mdpi.com/journal/
currentoncology](https://mdpi.com/journal/currentoncology)





Current Oncology

an Open Access Journal
by MDPI

Impact Factor 3.6
CiteScore 6.1
Indexed in PubMed



[mdpi.com/journal/
currentcol](https://mdpi.com/journal/currentcol)



About the Journal

Message from the Editor-in-Chief

I am honored and enthusiastic to serve as Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

Editor-in-Chief

Prof. Dr. Shahid Ahmed

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada

2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)